Amoxycillin & Potassium Clavulanate Tablets IP 500 / 125 mg

Trusted Antibacterial Therapy

ELTOCLAV 625 combines the proven power of Amoxycillin with the beta-lactamase inhibitor Clavulanate Potassium, ensuring reliable coverage for infections caused by resistant organisms.

Essential Facts

Regulatory Snapshot

Key product inputs are consolidated below. Fields without information are intentionally left blank for your regulatory or marketing team to update.

ELTOCLAV 625™
Proper & Generic Name Amoxycillin and Potassium Clavulanate Tablets IP 500 / 125 mg
Brand Name ELTOCLAV 625™
Marketed By Shed No. 44, Skylin Infra Hub, B/H Intas Pharma Vasna Chacharvadi Ahmedabad Gujarat India 382213
Batch Number UPT-2618
Date of Manufacturing 02/2026
Date of Expiry 07/2027
Manufacturing Licence Number MB/07/538&MNB/07/537
MRP 195.50
Specification High-potency antibacterial tablet for resistant infections

Clinical Highlights

  • Combines beta-lactam Amoxycillin with beta-lactamase inhibitor Clavulanate to overcome resistant pathogens.
  • Suitable for respiratory, ENT, skin, and soft-tissue infections caused by susceptible organisms.
  • Trusted formulation profile engineered for consistent plasma exposure and dependable clinical outcomes.